Investors largely expected the FOMC to cut rates by a quarter point.The Fedread more
The lack of clarity surrounding the U.S.-China trade war is what's really hitting global growth, says ex- Deputy Treasury Secretary Sarah Bloom Raskin.World Economyread more
China's economy has long relied on factors such high levels of investments and an expanding labor force for growth. Those growth drivers are running out of steam.China Economyread more
India could benefit from the fallout in the U.S.-China trade war, experts told CNBC — but much-needed reforms on land and labor could prove to be a challenge for companies...Asia Economyread more
New crash tests show the Tesla Model 3 and the Audi e-tron, are among the safest models out on the road. The results bolster the theory electric vehicles may be better...Autosread more
U.S. consumers and growth in sectors such as technology have offset declines in other American industries, says Tom Finke, chairman and CEO of investment management firm...US Economyread more
The FAA administrator's comments come on the eve of his visit to Boeing facilities outside Seattle. While there, he's scheduled to meet with Boeing executives and be briefed...Airlinesread more
Last weekend's attacks on oil facilities — and the spike in crude prices that followed — should show that the world needs to stop relying on oil, says Helen Clark.Energyread more
The photo depicts Canadian leader Justin Trudeau wearing a turban and robe, with dark makeup on his hands, face and neck. Liberal Party spokesman confirms the photo is of...Electionsread more
As the Fed was meeting to consider cutting interest rates, it lost control of the very benchmark rate that it manages.Market Insiderread more
CBS, CNN and other major media companies are starting to pull e-cigarette advertising off their airways, as the death toll from a mysterious vaping-related illness continues...Health and Scienceread more
A glut of patients who were prescribed Repatha, Amgen's treatment for high cholesterol, but couldn't pay for the pricey treatment, were top of mind in the company's decision to cut the drug's cost by 60 percent, Amgen Chairman and CEO Bob Bradway said Monday.
In October, Amgen cut the price for a biweekly dose of Repatha, bringing the annual $14,100 total, before discounts and rebates, to roughly $5,850. On Monday, the biotechnology giant announced another 60 percent price slash, this time to the cost of the monthly dose.
"We found too many patients were prescribed this therapy, but were struggling to pay for it at the pharmacy counter," Bradway told CNBC in an interview with Jim Cramer. "The reaction so far from physicians and from patients has been very, very encouraging."
While the positive reaction in itself may not make up for the money Amgen will lose, the number of patients that will reconsider taking the drug at its lower price was encouraging enough for Bradway, who has been CEO of Amgen since 2012.
"What we're finding is that patients that were walking away from the prescription — so, patients whose doctors had already identified them as being at high risk for heart attack and stroke — are now being able to get access to the medicine," Bradway said on "Mad Money."
Repatha treats high LDL cholesterol, the kind that heightens the risk of heart attack and stroke. It's also the main reason why $600 billion a year is spend on cardiovascular disease, Bradway said, adding that Repatha lowers LDL levels in patients by 63 percent, on average.
Amgen's stock rose 1.35 percent Monday, settling at $198.07 a share. The company made headlines in 2018 for pioneering Aimovig, the first drug specifically intended for migraine sufferers, and has seen that franchise grow by double digits.
Disclosure: Cramer's charitable trust owns shares of J.P. Morgan and Amgen.